Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Preservative-Free Tafluprost in Glaucoma/OHT
NCT01087671Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Apr 2010
- Primary completion
- Oct 2010
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of tafluprost in ocular hypertension, open-angle glaucoma (OAG), sponsored by Santen Pharmaceutical. Started Apr 2010; status: completed.
02
Drugs
tafluprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT01087671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01087671.